세계의 급성 골수성 백혈병 시장 규모 조사 및 예측 : 화학요법별(시타라빈, 안트라사이클린계 약물, 알킬화제, 대사길항제, 티로신 키나아제 억제제, 호르몬 요법, 기타 화학요법), 지역별 분석(2023-2030년)

Global Acute Myeloid Leukemia Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Acute Myeloid Leukemia (AML) is a form of blood cancer and bone marrow with excess immature white blood cells. It is characterized by the rapid proliferation of immature myeloid cells, which are a type of white blood cell responsible for fighting infections. These immature cells amass in the bone marrow in AML and obstruct the formation of healthy blood cells, resulting in symptoms and problems. The increasing prevalence of acute myeloid leukemia, the rising introduction of novel therapies, the rising emphasis on precision medicine, the surging adoption of immunotherapies, and increasing healthcare expenditure are the primary factors that are attributing to the market demand across the globe.

In addition, the rising geriatric population is acting as a catalyzing factor for market growth across the globe. According to the American Cancer Society, AML is usually occurred among the older population and is uncommon before the age of 45. Also, the average age for AML is nearly 68. The World Health Organization (WHO) reported that it is anticipated that the number of aging people increase from 1 billion in 2020 to 1.5 billion in 2030 which worldwide accounts for 1 in 6 people above 60. Hence, the rapidly growing geriatric population is more prone to be affected by acute myeloid leukemia, which is creating lucrative opportunities for market growth. Moreover, rising advancements in pharmacology and molecular biology to promote drug development, as well as the increasing investments in research and development are presenting various lucrative opportunities over the forecasting years. For instance, in May 2022, the FDA declared that they approved Tibsovo, Servier Pharmaceuticals LLC's ivosidenib in a mixture with azacitidine (azacitidine for injection) for novel diagnosed acute myeloid leukemia (AML). Additionally, it involves a susceptible IDH1 mutation identified by an FDA-approved test in adults aged 75 years and over or with comorbidities that prevent intensive induction chemotherapy. However, the stringent regulations on drugs and complications related to chemotherapy are restricting the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Myeloid Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing incidences of acute myeloid leukemia cases, rising technological advancements, and growing focus on patient-centric approaches. The American Cancer Society stated that in 2023, approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia were recorded. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government initiatives, an increasing number of clinical trials conducted, rising healthcare expenditure, and growing advancements in molecular diagnostics.

Major market players included in this report are:

• Novartis AG
• Genmab AS
• Otsuka Holdings Co. Ltd
• Sanofi-Aventis (Genzyme Corporation)
• Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sunesis Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Oncolyze Inc.

Recent Developments in the Market:

• In January 2022, Oncolyze announced that OM-301, a medication used to treat acute myeloid leukaemia (AML), had been granted FDA orphan drug designation.
• In December 2021, SNDX-5613, a highly specific oral menin inhibitor for the treatment of acute myeloid leukaemia (AML), was approved as an orphan drug by the European Commission.

Global Acute Myeloid Leukemia Market Report Scope:

• Historical Data: - 2020 - 2021
• Base Year for Estimation: - 2022
• Forecast period: - 2023-2030
• Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: - Chemotherapy, Region
• Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Chemotherapy:

• Cytarabine
• Anthracycline Drugs
• Alkylating Agents
• Anti-metabolites
• Tyrosine Kinase Inhibitors
• Hormonal Therapy
• Other Chemotherapies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Acute Myeloid Leukemia Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Acute Myeloid Leukemia Market, by Chemotherapy, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Acute Myeloid Leukemia Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Acute Myeloid Leukemia Market Dynamics

• 3.1. Acute Myeloid Leukemia Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevalence of acute myeloid leukemia
    • 3.1.1.2. Rising geriatric population
  • 3.1.2. Market Challenges
    • 3.1.2.1. Stringent regulations on drugs
    • 3.1.2.2. Complications related to chemotherapy
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising advancements in pharmacology and molecular biology to promote drug development
    • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Acute Myeloid Leukemia Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Acute Myeloid Leukemia Market, by Chemotherapy

• 5.1. Market Snapshot
• 5.2. Global Acute Myeloid Leukemia Market by Chemotherapy, Performance - Potential Analysis
• 5.3. Global Acute Myeloid Leukemia Market Estimates & Forecasts by Chemotherapy 2020-2030 (USD Billion)
• 5.4. Acute Myeloid Leukemia Market, Sub Segment Analysis
  • 5.4.1. Cytarabine
  • 5.4.2. Anthracycline Drugs
  • 5.4.3. Alkylating Agents
  • 5.4.4. Anti-metabolites
  • 5.4.5. Tyrosine Kinase Inhibitors
  • 5.4.6. Hormonal Therapy
  • 5.4.7. Other Chemotherapies

Chapter 6. Global Acute Myeloid Leukemia Market, Regional Analysis

• 6.1. Top Leading Countries
• 6.2. Top Emerging Countries
• 6.3. Acute Myeloid Leukemia Market, Regional Market Snapshot
• 6.4. North America Acute Myeloid Leukemia Market
  • 6.4.1. U.S. Acute Myeloid Leukemia Market
    • 6.4.1.1. Chemotherapy breakdown estimates & forecasts, 2020-2030
  • 6.4.2. Canada Acute Myeloid Leukemia Market
• 6.5. Europe Acute Myeloid Leukemia Market Snapshot
  • 6.5.1. U.K. Acute Myeloid Leukemia Market
  • 6.5.2. Germany Acute Myeloid Leukemia Market
  • 6.5.3. France Acute Myeloid Leukemia Market
  • 6.5.4. Spain Acute Myeloid Leukemia Market
  • 6.5.5. Italy Acute Myeloid Leukemia Market
  • 6.5.6. Rest of Europe Acute Myeloid Leukemia Market
• 6.6. Asia-Pacific Acute Myeloid Leukemia Market Snapshot
  • 6.6.1. China Acute Myeloid Leukemia Market
  • 6.6.2. India Acute Myeloid Leukemia Market
  • 6.6.3. Japan Acute Myeloid Leukemia Market
  • 6.6.4. Australia Acute Myeloid Leukemia Market
  • 6.6.5. South Korea Acute Myeloid Leukemia Market
  • 6.6.6. Rest of Asia Pacific Acute Myeloid Leukemia Market
• 6.7. Latin America Acute Myeloid Leukemia Market Snapshot
  • 6.7.1. Brazil Acute Myeloid Leukemia Market
  • 6.7.2. Mexico Acute Myeloid Leukemia Market
• 6.8. Middle East & Africa Acute Myeloid Leukemia Market
  • 6.8.1. Saudi Arabia Acute Myeloid Leukemia Market
  • 6.8.2. South Africa Acute Myeloid Leukemia Market
  • 6.8.3. Rest of Middle East & Africa Acute Myeloid Leukemia Market

Chapter 7. Competitive Intelligence

• 7.1. Key Company SWOT Analysis
  • 7.1.1. Company 1
  • 7.1.2. Company 2
  • 7.1.3. Company 3
• 7.2. Top Market Strategies
• 7.3. Company Profiles
  • 7.3.1. Novartis AG
    • 7.3.1.1. Key Information
    • 7.3.1.2. Overview
    • 7.3.1.3. Financial (Subject to Data Availability)
    • 7.3.1.4. Product Summary
    • 7.3.1.5. Recent Developments
  • 7.3.2. Genmab AS
  • 7.3.3. Otsuka Holdings Co. Ltd
  • 7.3.4. Sanofi-Aventis (Genzyme Corporation)
  • 7.3.5. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
  • 7.3.6. Pfizer Inc.
  • 7.3.7. F. Hoffmann-La Roche Ltd
  • 7.3.8. Sunesis Pharmaceuticals Inc.
  • 7.3.9. Astellas Pharma Inc.
  • 7.3.10. Oncolyze Inc.

Chapter 8. Research Process

• 8.1. Research Process
  • 8.1.1. Data Mining
  • 8.1.2. Analysis
  • 8.1.3. Market Estimation
  • 8.1.4. Validation
  • 8.1.5. Publishing
• 8.2. Research Attributes
• 8.3. Research Assumption